Synonym
Quinidine bisulfate; Biquin durules; Chinidin VUFB; Kinilentin; Optochinidin
IUPAC/Chemical Name
Cinchonan-9-ol, 6'-methoxy-, (9S)-, sulfate (1:1)
InChi Key
AKYHKWQPZHDOBW-VJAUXQICSA-N
InChi Code
InChI=1S/C20H24N2O2.H2O4S/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18;1-5(2,3)4/h3-6,8,11,13-14,19-20,23H,1,7,9-10,12H2,2H3;(H2,1,2,3,4)/t13-,14-,19+,20-;/m0./s1
SMILES Code
C=C[C@@H](C[N@@]1CC2)[C@@H]2C[C@@H]1[C@@H](O)C3=CC=NC4=CC=C(OC)C=C34.O=S(O)(O)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
422.49
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Belhassen B, Glick A, Viskin S. Efficacy of quinidine in high-risk patients with Brugada syndrome. Circulation. 2004 Sep 28;110(13):1731-7. doi: 10.1161/01.CIR.0000143159.30585.90. Epub 2004 Sep 20. PMID: 15381640.
2: Olsson G. To the editor--Market withdrawal of quinidine bisulfate (Kinidin Durules) in 2006. Heart Rhythm. 2010 Jun;7(6):864. doi: 10.1016/j.hrthm.2010.03.010. Epub 2010 Mar 10. PMID: 20226273.
3: Jamaludin A, Mohamed M, Navaratnam V, Mohamed N, Yeoh E, Wernsdorfer W. Single-dose comparative kinetics and bioavailability study of quinine hydrochloride, quinidine sulfate and quinidine bisulfate sustained-release in healthy male volunteers. Acta Leiden. 1988;57(1):39-46. PMID: 3245401.
4: Mahon WA, Mayersohn M, Inaba T. Disposition kinetics of two oral forms of quinidine. Clin Pharmacol Ther. 1976 May;19(5 Pt 1):566-75. doi: 10.1002/cpt1976195part1566. PMID: 1277713.
5: Bottorff MB, Lalonde RL, Straughn AB. Comparison of high pressure liquid chromatography and fluorescence polarization immunoassay to assess quinidine pharmacokinetics. Biopharm Drug Dispos. 1987 May-Jun;8(3):213-21. doi: 10.1002/bdd.2510080303. PMID: 3297181.
6: Remon JP, Belpaire F, Van Severen R, Braeckman P. Interaction of antacids with antiarrhythmics. V. Effect of aluminium hydroxide and magnesium oxide on the bioavailability of quinidine, procainamide and propranolol in dogs. Arzneimittelforschung. 1983;33(1):117-20. PMID: 6681962.
7: Hii JT, Wyse DG, Gillis AM, Cohen JM, Mitchell LB. Propafenone-induced torsade de pointes: cross-reactivity with quinidine. Pacing Clin Electrophysiol. 1991 Nov;14(11 Pt 1):1568-70. doi: 10.1111/j.1540-8159.1991.tb02729.x. PMID: 1721143.
8: Huminer D, Dux S, Rosenfeld JB, Pitlik SD. Inadvertent sulfonylurea-induced hypoglycemia. A dangerous, but preventable condition. Arch Intern Med. 1989 Aug;149(8):1890-2. PMID: 2504124.
9: Rakhmanova MM, Sokolov SF. [Efficacy and safety of allapinine and quinidine bisulphate in the treatment of patients with persistent atrial fibrillation after cardioversion]. Kardiologiia. 2014;54(9):33-8. Russian. doi: 10.18565/cardio.2014.9.33-38. PMID: 25702400.
10: Knapp W, Lechleitner P. Relative Bioverfügbarkeit sowie Einfluss von Chindin in Form einer Retard-Zubereitung auf Blutdruck und EKG von gesunden Probanden [Relative bioavailability and influence of a quinidine retard-formulation on blood-pressure and ECG in healthy volunteers (author's transl)]. Arzneimittelforschung. 1981;31(9):1482-6. German. PMID: 7197960.
